A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.

Zahi Ibrahim Mitri,Jacqueline Vuky,Kathleen Kemmer,Michael A. Savin,Swapnil Parmar,Annette Kolodzie,Brett Johnson,Rochelle Williams-Belizaire,Joe W. Gray,Gordon B. Mills

A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.

2019

Zahi Ibrahim Mitri
Jacqueline Vuky
Kathleen Kemmer
Michael A. Savin
Swapnil Parmar
Annette Kolodzie
Brett Johnson
Rochelle Williams-Belizaire
Joe W. Gray
Gordon B. Mills

TPS1111Background: There is an urgent need to develop novel non chemotherapy treatments for metastatic triple negative breast cancer (mTNBC) patients who otherwise have a poor prognosis. Immune che...

Keywords:

Wild type
Olaparib
Durvalumab
Triple-negative breast cancer
Oncology
Pathology
Internal medicine
Medicine
Immune system
poor prognosis
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations